24/7 Market News Snapshot 22 May, 2025 – Immix Biopharma, Inc. Common Stock (NASDAQ:IMMX)

May 22, 2025

DENVER, Colo., 22 May, 2025 (www.247marketnews.com) – (Nasdaq:IMMX) are discussed in this article.
Immix Biopharma, Inc. (Nasdaq:IMMX) is experiencing a notable surge in its stock performance, opening at $2.06 and surpassing the previous close of $2.090 to reach approximately $2.619, marking an increase of over 25.31%. This heightened trading activity, with a volume of 2.54 million shares, reflects robust investor interest and confidence in the company’s future prospects, particularly as attention within the biopharmaceutical sector intensifies.

Concurrently, Immix Biopharma has announced groundbreaking results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201, a CAR-T cell therapy targeting relapsed/refractory AL Amyloidosis. The trial’s findings, set for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, reveal a striking complete response (CR) rate of 71% among the initial patient cohort. All treated participants demonstrated normalization of pathological disease markers, with no relapses or adverse safety events reported thus far.

Dr. Heather Landau, the lead investigator from Memorial Sloan Kettering Cancer Center, will present these findings during the ASCO event on June 3, 2025, offering further insights into endpoint analyses and the therapy’s impact on organ responses. Immix’s CEO, Dr. Ilya Rachman, expressed enthusiasm regarding the study’s results, emphasizing their potential to revolutionize treatment approaches for this challenging disease. The company also aims to capitalize on its recent FDA Regenerative Medicine Advanced Therapy (RMAT) designation as it advances both NXC-201 and its broader clinical initiatives.

As the incidence of relapsed/refractory AL Amyloidosis rises, the urgent demand for innovative treatment options becomes increasingly evident. Immix Biopharma is resolutely focused on meeting this unmet need through the development and advancement of its promising therapies. The forthcoming presentation at ASCO is anticipated to shine a spotlight on the transformational potential of NXC-201 in the treatment landscape.

Related news for (IMMX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.